Investigating the Miracle Biologic Lecanemab for Alzheimer's Disease - Part 3
Lecanemab’s harms evidence base from the Phase II trial
Following on from our previous two posts
We look further into the “Core” Phase II study 201, which enrolled 856 people with early Alzheimer’s Disease (AD). Of these, 180 went on to participate in the OLE (Open-Label…